**Option 1: Concise Summary (Bulleted)** - **Product:** 10mL vial at a concentration of 300mg/mL. - **History:** Originally introduced as a human-grade drug (Parenabol by Ciba in the 1950s) but discontinued in the 1970s. Now primarily a veterinary steroid (Equipoise, currently owned by Fort Dodge) and available via underground labs. - **Structural Profile:** A testosterone derivative with an added double bond at C1-C2. This reduces its androgenic and estrogenic activity compared to testosterone. - **Key Differences:** Often confused with Nandrolone (Deca), but chemically distinct; **Eq** has no progestin activity, unlike Nandrolone. - **Pharmacokinetics:** The large Undecylenate ester provides a peak release at 3–4 days post-injection and a sustained release lasting approximately 21 days. - **Estrogenic Activity:** Aromatizes at roughly 50% of testosterone's rate, leading to lower estrogenic side effects and "cleaner" (less watery) muscle gains. - **Mechanism:** Enhances protein synthesis, nitrogen retention, inhibits glucocorticoids, boosts IGF-1, and increases red blood cell count (RBC). - **RBC Caution:** While RBC elevation can be rapid, significant health risks are generally associated only with excessively high doses used over prolonged periods. --- **Option 2: Clinical/Professional Summary** **Boldenone Undecylenate (10mL, 300mg/mL)** Originally developed by Ciba in the 1950s as the human-grade drug Parenabol, Boldenone was later discontinued for human use and is now predominantly a veterinary steroid, famously marketed as Equipoise (currently owned by Fort Dodge). Structurally, it is testosterone with an additional double bond between carbons 1 and 2, which diminishes its androgenic and estrogenic effects. Contrary to popular belief, it shares little similarity with Nandrolone (Deca Durabolin), as it lacks progestin activity. The Undecylenate ester facilitates a peak plasma concentration 3–4 days post-injection, with effects extending up to 21 days. The compound aromatizes at approximately half the rate of testosterone, reducing estrogenic side effects and promoting leaner tissue gains. Mechanistically, it enhances protein synthesis, nitrogen retention, IGF-1 production, and erythropoiesis (red blood cell count). Although rapid RBC elevation is noted, adverse effects are primarily linked to excessive, long-term dosing, while moderate elevations offer clear athletic benefits. --- **Option 3: At-a-Glance (Fact Sheet Style)** **Dosage Form:** 10mL multi-dose vial (300mg/mL) | **Category** | **Details** | | :--- | :--- | | **Active Substance** | Boldenone Undecylenate | | **Brand History** | Human: Parenabol (Ciba, 1950s–70s); Veterinary: Equipoise (Fort Dodge) | | **Structural Relation** | Testosterone derivative with a C1-C2 double bond (reduces androgenic/estrogenic effects). | | **Common Misconception** | Not similar to Nandrolone; Boldenone lacks progestin activity. | | **Release Profile** | Peak at ~3–4 days; active release for ~21 days. | | **Estrogen Conversion** | ~50% of testosterone's rate (lower risk of estrogenic sides; cleaner gains). | | **Primary Effects** | ↑ Protein synthesis, ↑ Nitrogen retention, ↑ IGF-1, ↑ RBC count. | | **Safety Note** | RBC elevation is fast but generally safe unless extreme doses are used long-term. | --- **Option 4: Shortened Academic Paragraph** Boldenone Undecylenate (supplied as 10mL at 300mg/mL) is a testosterone analog distinguished by a C1-C2 double bond, which reduces its androgenic and estrogenic potential. First marketed as Parenabol for human use in the 1950s, it is now exclusively a veterinary product (Equipoise). Its long Undecylenate ester ensures a peak release 3–4 days after injection and a sustained effect over approximately three weeks. Unlike nandrolone, it exhibits no progestin activity. The compound aromatizes at half the rate of testosterone, promoting relatively dry muscle gains. Its anabolic mechanisms include enhanced nitrogen retention, protein synthesis, and IGF-1 production, alongside a notable increase in erythropoiesis. While the latter can occur rapidly, clinical concerns are generally confined to regimens involving excessively high doses over extended durations.

REFUND POLICY: Subjective per Case